Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biseko is a virus-inactivated, standardized human serum protein solution (5%) derived from pooled human plasma. It contains a physiological distribution of serum proteins, including albumin (approximately 31 g/L), immunoglobulins (IgG, IgA, IgM), transport proteins (such as transferrin and haptoglobin), and various clotting factors and inhibitors. Unlike standard albumin solutions, Biseko provides a full spectrum of serum antibodies, offering passive immunity and potential anti-inflammatory benefits in critically ill patients. It is primarily indicated for the treatment of hypoproteinemia, volume replacement, and as an adjunctive therapy in systemic inflammatory response syndrome (SIRS) and sepsis. The product is manufactured by Biotest AG and is administered via intravenous infusion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biseko.